Pulse Biosciences (PLSE) EBITDA Margin (2021 - 2026)

Pulse Biosciences (PLSE) posted EBITDA Margin of 5823.04% for Q2 2026, up 15.78% on a QoQ basis from 6914.02% in Q4 2025.

Analysis

Pulse Biosciences (PLSE) EBITDA Margin (2021 - 2026) Analysis & Trends

Pulse Biosciences has reported EBITDA Margin for 4 years, with the latest figure at 5823.04% in Q2 2026.

On a quarterly basis, EBITDA Margin changed N/A year-over-year to 5823.04% in Q2 2026; TTM through Jun 2026 was 10735.59%, a N/A change from a year earlier, with the FY2025 full-year figure at 21982.57%, changed N/A from the prior year.
EBITDA Margin was 5823.04% for Q2 2026 at Pulse Biosciences, up from 6914.02% in the prior quarter.
The five-year high for EBITDA Margin was 97166.67% in Q4 2022, with the low at 23682.56% in Q3 2025.
Average EBITDA Margin over 3 years is 8697.57%, with a median of 5247.19% recorded in 2026.
The largest YoY upside for EBITDA Margin was 9899250 bps in 2022 against a maximum downside of 9899250 bps in 2022.
Over 3 years, EBITDA Margin stood at 97166.67% in 2022, then plunged by 107 bps to 6914.02% in 2025, then climbed by 16 bps to 5823.04% in 2026.
The last three EBITDA Margin figures came in at 5823.04% (Q2 2026), 6914.02% (Q4 2025), and 23682.56% (Q3 2025), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Abbott Laboratories	179.79 Bn	174.18 Bn	7.27 Bn	13.44%
2	Intuitive Surgical	127.69 Bn	122.47 Bn	1.96 Bn	33.60%
3	Medtronic	117.23 Bn	108.41 Bn	6.34 Bn	18.08%
4	Stryker	103.55 Bn	100.07 Bn	4.50 Bn	25.18%
5	Boston Scientific	63.24 Bn	62.70 Bn	3.85 Bn	21.65%
6	Edwards Lifesciences	49.97 Bn	45.72 Bn	1.35 Bn	29.48%
7	Alcon	32.83 Bn	31.37 Bn	1.68 Bn	0.40%
8	Dexcom	32.30 Bn	30.35 Bn	830.00 Mn	24.33%
9	Steris	20.73 Bn	20.25 Bn	684.20 Mn	19.15%
10	Pulse Biosciences	3.76 Bn	3.76 Bn	161,000.00	-5,823.04%

Historic Data

Download Data